QUICKprep · 26 October 2026New research highlights why bacterial viability, sample cleanliness and inoculum quality matter when preparing positive blood cultures for rapid phenotypic AST.
Read article →QUICKprep · 25 June 2026Read article →QUICKprep · 24 June 2026Read article →Science · 23 June 2026Read article →QUICKprep · 19 June 2026A published study of 281 positive urine samples evaluated QUICKprep as a route to concentrated, low-debris microbial material for rapid MALDI-TOF identification.
Read article →QUICKprep · 10 April 2026A published study found that FASTINOV sample preparation supported reliable MALDI-TOF identification directly from positive blood cultures, creating a common starting point for rapid ID and AST workflows.
Read article →2025 · PublicationA Portuguese healthcare economic model reported reductions in mortality, hospital stay and cost compared with standard and rapid AST pathways.
Read article →2024 · EventFASTINOV presented its same-shift 2-hour AST and new hospital evidence at the Spanish national congress.
Read article →2024 · EventCustomer and demonstration-site evidence showed accurate AST reports in the same shift that blood cultures flagged positive.
Read article →2024 · EventThe partnership presented ultra-rapid AST at the XIII Portuguese National Clinical Pathology Congress in Algarve.
Read article →2024 · EventThe 2024 programme highlighted real-world hospital use, customer evaluations and three scientific posters.
Read article →2023 · CustomerThe oncology hospital selected FASTINOV's technology for its clinical infrastructure.
Read article →2023 · PublicationEvaluation data from Coimbra and Hospital Garcia de Orta supported approximately 2-hour AST and same-shift reporting.
Read article →2023 · EvaluationA new Spanish hospital evaluation expanded the real-world assessment of ultra-rapid AST.
Read article →2023 · FinancingExplorer Investments and Quilaban supported further R&D, commercialization and international growth.
Read article →2023 · EventThe congress focused on bloodstream infection diagnosis, antimicrobial resistance and same-day AST.
Read article →2023 · EvaluationThe milestone captured the expansion of hospital evaluation activity in Portugal.
Read article →2023 · EventThe company invited Spanish clinical microbiology leaders to discuss integrating rapid AST into bloodstream infection workflows.
Read article →2023 · EventThe company presented its technology and scientific posters at the European congress.
Read article →2023 · EventThe sponsored symposium covered sepsis, two-hour susceptibility testing, first hospital use and implementation implications.
Read article →2023 · EvaluationThe first hospital evaluation marked the beginning of a wider real-world validation programme.
Read article →2022 · RecruitmentFASTINOV opened a pivotal role supporting the launch of its AST kits in Europe.
Read article →2022 · WebinarThe webinar discussed the role of rapid AST technologies in the modern response to sepsis.
Read article →2022 · CongressThe event addressed infection control, antimicrobial resistance and the need for faster susceptibility results.
Read article →2022 · CongressThe company announced its presence at the 32nd European Congress of Clinical Microbiology and Infectious Diseases.
Read article →2022 · CommercialThe launch introduced FASTgrampos, FASTgramneg and FASTcolistin for ultra-rapid bloodstream infection AST.
Read article →2023 - PartnershipThe partnership brought FASTINOV's ultra-rapid 2-hour AST technology together with Beckman Coulter flow-cytometry analyzers for clinical microbiology laboratories.
Read article →